These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Re: antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Kaplan SA J Urol; 2011 Jan; 185(1):226. PubMed ID: 22082930 [No Abstract] [Full Text] [Related]
7. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819 [TBL] [Abstract][Full Text] [Related]
8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342 [TBL] [Abstract][Full Text] [Related]
9. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643 [TBL] [Abstract][Full Text] [Related]
12. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299 [TBL] [Abstract][Full Text] [Related]
13. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175 [TBL] [Abstract][Full Text] [Related]
14. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334 [TBL] [Abstract][Full Text] [Related]
15. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Schally AV; Varga JL; Engel JB Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344 [TBL] [Abstract][Full Text] [Related]
16. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia. Kumar R; Malla P; Kumar M Expert Opin Drug Discov; 2013 Aug; 8(8):1013-27. PubMed ID: 23662859 [TBL] [Abstract][Full Text] [Related]
17. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue. Szalontay L; Benveniste RJ; Schally AV; Vidaurre I; Nadji M; Zarandi M; Block NL; Kovacs M Neuroendocrinology; 2012; 96(1):81-8. PubMed ID: 22377963 [TBL] [Abstract][Full Text] [Related]
19. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358 [TBL] [Abstract][Full Text] [Related]
20. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]